

DESIGN AND SYNTHESIS OF BIOLOGICALLY RELEVANT HETEROCYCLES

DESHMUKH MAHESH SUBHASHRAO



DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
DECEMBER 2017

DESIGN AND SYNTHESIS OF BIOLOGICALLY RELEVANT HETEROCYCLES

by

DESHMUKH MAHESH SUBHASHRAO

Department of Chemistry

Submitted

in fulfillment of the requirements of the degree of Doctor of Philosophy

to the



**INDIAN INSTITUTE OF TECHNOLOGY DELHI
DECEMBER 2017**

CERTIFICATE

This is to certify that the thesis entitled, “**DESIGN AND SYNTHESIS OF BIOLOGICALLY RELEVANT HETEROCYCLES**” being submitted by **Mr. Deshmukh Mahesh Subhashrao** to the Indian Institute of Technology, Delhi, for the award of the degree of **Doctor of Philosophy** in chemistry, is a record of bonafide research work carried out by him. He has worked under my guidance and supervision. He has fulfilled all the requirements for the submission of this thesis, which to my knowledge has reached the requisite standard.

The results embodied in this thesis have not been submitted, in part or in full, to any other university or institute for award of any degree or diploma.

Dr. NIDHI JAIN

Associate Professor

Department of Chemistry

Indian Institute of Technology Delhi

New Delhi-110016

Date:

ACKNOWLEDGEMENTS

I wish to express my deepest appreciation to my supervisor **Dr. Nidhi Jain** for her continuous support and constant encouragement throughout my Ph.D. tenure. Her generous and appreciative nature helped me easily go through the tough time of my tenure. I would also like to thank her for not only improving my organic chemistry knowledge but also for improving English language as well as publication writing skills. She persistently conveyed a spirit of adventure in research which motivated me to try new things and explore the unexplored. I could not have imagined of having a better advisor and mentor for my Ph.D. research work. Without her guidance and constant support this thesis would not have been possible.

I am equally thankful to my mentor Dr. Biswajit Das for his valuable guidance, timeless support and uninterrupted faith throughout my professional career. His valuable advice, constructive criticism and active participation during discussions provided me different perspective to look at the problems. He was always pushing me to complete the work in stipulated time.

I could also like to extend my sincere thanks to SRC committee members Prof. Nalin Pant, Prof. Ravi Shankar and Prof. Veena Koul for their thoughtful suggestions, which motivated me to understand my work with broader perspective.

I am also indebted to Daiichi Sankyo India Pharma Pvt. Ltd. (DSIN) and Indian Institute of Technology, Delhi (IITD) for giving me the opportunity to pursue my Ph.D. degree and also for providing the necessary facilities and funds to conduct my research work.

I would like to dedicate this thesis to my teacher Dr. Vijay Khanna for his countless efforts and motivation for making me a passionate and dedicated chemistry student. I am grateful for his constant support, guidance, appreciation and encouragement. He always inspired me to work hard to achieve my goals. The words are not enough to express my feelings towards him.

A very special gratitude goes to my DSIN colleagues Abhishek Gupta, Diksha Singh, Palak Gulati, Dr. Tarun Mathur, Dr. Sameul Raj and Dr. Tridip Chaira for their support in antibacterial, DMPK and docking studies. My warm appreciation to my IITD friends Ananya, Awadh, Chanchal, Nisha, Poonam, Pramod, Shyam, Sandeep, Pradeep, Vimal and Rahul not only for their support but also for friendly discussions. Your company made my stay at IIT Delhi fantastic and memorable.

I am also obliged to my parents Mr. Subhashrao and Mrs. Surekha for their constant encouragement to achieve my goals even though they really don't understand what it is all about! Further, I am also thankful to my wife Archana and my children Shaurya and Soumya for their understanding and support during this tenure. I would like to thank all my well wishers, friends and colleagues for their support and encouragement.

Last but not the least; I rest all my achievements to the God for providing me enough strength, passion and wisdom to continuously work to accomplish them.

Mahesh Deshmukh

ABSTRACT

Chapter 1: An overview of the importance of heterocyclic compounds in different fields such as natural products, transition metal-ligands, organocatalysts and medicines has been provided. Further, different approaches used for their synthesis have also been discussed.

Chapter 2: An unprecedented one-pot synthesis of substituted 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, and 1,4-benzodioxines from activated *ortho*-halonitrobenzenes has been discussed. The reaction proceeds by dual nucleophilic aromatic substitution (S_NAr) of halogen followed by substitution of the nitro group by secondary diamines, secondary amino alcohols, and diols respectively.

Chapter 3: An unprecedented zinc triflate catalyzed selective C-benylation of anilides and heteroaryl amides with benzyl chlorides having electron-donating group at *para*-position has been demonstrated. The methodology offers moderate to high yield of para-amido substituted diaryl and arylheteroarylmethanes, uses cheap and easily available benzyl chlorides as the benzylating agent, catalytic amount of zinc triflate, and takes place under ambient conditions. The methodology has also been applied for preparing dimethoxydiarylmethanes in good yields, which are the key precursors for synthesis of phenolic natural products.

Chapter 4: Design, synthesis and antibacterial evaluation of a series of novel oxazolidinone derivatives with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities has been carried out. The detailed structure activity relation obtained by modifications at C-ring as well as C5-side chain has been discussed. Further, the drug-like properties of the selected compounds have also been determined. Docking studies of selected compounds has been performed to understand the increased activity of the synthesized compounds.

सार

अध्याय 1: विभिन्न उत्पादों जैसे कि प्राकृतिक उत्पादों, संक्रमण धातु-अंगों, कार्बनिक पदार्थों और दवाइयां जैसे विभिन्न क्षेत्रों में हेरोर्काइक्लिक यौगिकों के महत्व का अवलोकन किया गया है। इसके अलावा, उनके संश्लेषण के लिए इस्तेमाल किए गए विभिन्न तरीकों पर भी चर्चा हुई है।

अध्याय 2: एवजी 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, और सक्रिय ऑर्थो-halonitrobenzenes से 1,4-benzodioxines की एक अभूतपूर्व एक पॉट संश्लेषण चर्चा की गई। क्रमशः द्वितीयक नायकों, माध्यमिक अमीनो अल्कोहल, और डायल द्वारा नाइट्रो ग्रुप के प्रतिस्थापन के बाद दोहरे न्यूक्लियोफिलिक सुगन्धित प्रतिस्थापन (एसएनएआर) के हलोजन द्वारा प्रतिक्रिया की गई।

अध्याय 3: पैरामीशन में इलेक्ट्रॉन-दान देने वाले समूह वाले बेंज़िल क्लोराइड के साथ अनियमित जस्ता ट्रिप्लेट ने चयनात्मक सी-बेंज़िलेशन और अनियमितों के हेटेरोअल एमिड्स का प्रदर्शन किया है। पद्धति, पैरा-amido की उच्च उपज के लिए उदार diaryl और arylheteroarylmethanes प्रतिस्थापित प्रदान करता है benzylating एजेंट के रूप में सस्ते और आसानी से उपलब्ध बेंजाइल क्लोराइड, जस्ता triflate के उत्प्रेरक राशि का उपयोग करता है, और परिवेश की स्थिति के तहत जगह लेता है। फीनोलॉजिकल प्राकृतिक उत्पादों के संश्लेषण के लिए महत्वपूर्ण पूर्ववर्ती हैं, जो अच्छी पैदावार में डायमिथॉक्सीडायरीमिथेन्स तैयार करने के लिए भी कार्यप्रणाली लागू की गई है।

अध्याय 4: डिज़ाइन, संश्लेषण और विभिन्न फ्यूज़ हेटेरोराइल सी-रिंग्स वाले हाइड्रोजन बांड दाता और हाइड्रोजन बांड स्वीकर्ता कार्यात्मकताओं के साथ उपन्यास ऑक्सोजोलिकिनन डेरिवेटिव की एक श्रृंखला का एंटीबेक्टीयर मूल्यांकन। सी-अंगूठी और सी 5-साइड चैन पर संशोधनों से प्राप्त विस्तृत संरचना गतिविधि संबंध पर चर्चा की गई है। इसके अलावा, चयनित यौगिकों की दवा जैसे गुणों को भी निर्धारित किया गया है। संश्लेषित यौगिकों की वृद्धि की गतिविधि को समझने के लिए चुने हुए यौगिकों के अध्ययन को डॉकिंग किया गया है।

TABLE OF CONTENTS

	Page No.
Certificate.....	i
Acknowledgements	ii
Abstract	iv
List of Figures	xi
List of Tables	xiii
List of Schemes.....	xiv
Glossary of Symbols and Abbreviations.....	xvii
Material and Methods	xxiii

Chapter 1: Introduction

1.1. Importance of heterocyclic compounds.....	2
1.1.1. Heterocyclic compounds in living systems.....	2
1.1.2. Heterocyclic natural products.....	4
1.1.3. Heterocyclic compounds as metal ligands in organic synthesis.....	4
1.1.4. Heterocyclic compounds as organocatalyst.....	5
1.1.5. Heterocycles as drug molecules.....	6
1.1.5.1. Anticancer drugs.....	6
1.1.5.2. Drugs acting on Central Nervous System (CNS).....	7
1.1.5.3. Drugs acting on Cardiovascular System (CVS).....	8
1.1.5.4. Antiviral drugs.....	9
1.1.5.5. Antibacterial drugs.....	10
1.2. Synthesis of heterocyclic compounds.....	11
1.2.1. Nucleophilic Aromatic Substitution (S_NAr) reaction.....	11

1.2.1.1. S _N Ar reaction by addition-elimination mechanism.....	11
1.2.1.2. S _N Ar reaction by S _N 1 mechanism.....	12
1.2.1.3. S _N Ar reaction by benzyne mechanism.....	12
1.2.1.4. Radical-nucleophilic aromatic substitution (S _{RN} 1) reaction.....	13
1.2.1.5. S _N Ar reaction via ANRORC mechanism.....	14
1.2.1.6. Vicarious nucleophilic substitution.....	14
1.2.2. Lewis acid catalyzed reactions.....	15
1.2.2.1. Zinc catalyzed reactions.....	15
1.2.2.1.1. Allenylation of aldehyde.....	15
1.2.2.1.2. Cyclization reactions.....	17
1.2.2.1.3. Asymmetric synthesis.....	17
1.2.2.1.4. Cycloaddition reactions.....	18
1.2.2.1.5. Cross coupling reactions.....	18
1.2.3. Suzuki cross coupling.....	19
1.2.3.1. Synthesis of pharmaceutical drugs.....	19
1.2.3.2. Synthesis of unnatural amino acids.....	20
1.2.3.3. Natural product synthesis.....	21
1.3. References.....	23
Chapter 2: Dual S_NAr Reaction of Activated <i>ortho</i>-Halonitrobenzene: Direct Synthesis of Substituted 1,2,3,4-Tetrahydroquinoxalines, 2,3-Dihydro-1,4-benzoxazines, and 1,4-Benzodioxines, and their Antibacterial Evaluation	
2.1. Introduction.....	29
2.2. Results and Discussion.....	40

2.2.1. Synthesis of 1,2,3,4-tetrahydroquinoxaline derivatives.....	40
2.2.2. Synthesis of 3,4-dihydrobenzoxazine derivatives.....	45
2.2.3. Synthesis of benzodioxine derivatives.....	46
2.2.4. Proposed mechanism.....	47
2.2.4.1. Evidence for the proposed mechanism.....	47
2.2.5. Antibacterial evaluation.....	48
2.3. Conclusions.....	50
2.4. Experimental section.....	51
2.4.1. General Remarks.....	51
2.4.2. General procedure for synthesis of 1,2,3,4-tetrahydroquinoxalines (91a-m).....	51
2.4.3. Procedure for synthesis of 4-methyl-1-phenyl-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile (91n).....	52
2.4.4. General procedure for synthesis of 3,4-dihydro-2H-1,4-benzoxazines (93a-o).....	52
2.4.5. General procedure for synthesis of 2,3-dihydro-1,4-benzodioxines (95a-c).....	52
2.4.6. Procedure for synthesis of <i>tert</i> -butyl-{2-[(5-cyano-2-nitrophenyl)(methyl)amino]ethyl} carbamate (98).....	53
2.4.7. Procedure for synthesis of 3-[(2-aminoethyl)(methyl)amino]-4-nitrobenzonitrile hydrochloride (99).....	53
2.4.8. Procedure for synthesis of 4-methyl-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile (100).....	54

2.4.9. Procedure for antibacterial activity determination.....	54
2.4.10. Spectral data.....	55
2.4.11. ^1H and ^{13}C NMR spectra.....	65
2.5. References.....	103
 Chapter 3: Zinc Triflate Catalyzed C-Benzylolation for Chemo- and Regio-selective Synthesis of Amido Substituted Diaryl and Arylheteroarylmethanes, and their Antibacterial Evaluation	
3.1. Introduction.....	108
3.2. Results and Discussion.....	116
3.2.1. C-Benzylolation of anilides and carbamates.....	116
3.2.2. C-Benzylolation of heterocyclic derivatives.....	124
3.2.3. C-Benzylolation of anisole derivatives.....	125
3.2.4. Synthesis of natural product.....	126
3.2.5. Antibacterial evaluation.....	131
3.3. Conclusions.....	133
3.4. Experimental section.....	133
3.4.1. General Remarks.....	133
3.4.2. Procedure for synthesis of ethyl phenylcarbamate (65c).....	134
3.4.3. Procedure for synthesis of amido substituted diarylmethanes (68a-s).....	134
3.4.4. Procedure for synthesis of aryl-heteroarylmethanes (70a-g).....	135
3.4.5. Procedure for synthesis of 4,4'-dimethoxydiarylmethanes (72a-c).....	135
3.4.6. Procedure for synthesis of 2,4-bis(4-methoxybenzyl)anisole (75).....	135

3.4.7. Procedure for time-dependent UV-Vis monitoring of the reaction progress.....	136
3.4.8. Procedure for antibacterial activity determination.....	137
3.4.9. Spectral data.....	137
3.4.10. ¹ H and ¹³ C NMR spectra.....	146
3.5. References.....	175

Chapter 4: Design, Synthesis and Antibacterial Evaluation of Oxazolidinones with Novel Heterocyclic C-Ring Substructure

4.1. Introduction.....	180
4.2. Results and Discussion.....	190
4.2.1. Synthesis and antibacterial evaluation.....	190
4.2.2. Molecular modeling analysis.....	200
4.2.3. <i>In vitro</i> physchem and ADME profiling.....	203
4.3. Conclusions.....	204
4.4. Experimental section.....	205
4.4.1. General Remarks.....	205
4.4.2. General procedure for borylation <i>in situ</i> Suzuki coupling (22a-n).....	205
4.4.3. Synthesis of [(5 <i>R</i>)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate (23).....	206
4.4.4. Synthesis of (<i>R</i>)-5-(azidomethyl)-3-(3-fluoro-4-iodophenyl)oxazolidin-2-one (24).....	206
4.4.5. Synthesis of (<i>S</i>)-5-(aminomethyl)-3-(3-fluoro-4-iodophenyl)oxazolidin-2-one (25).....	206

4.4.6. Synthesis of <i>tert</i> -butyl {[(5 <i>S</i>)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl] methyl} carbamate (26).....	207
4.4.7. Synthesis of <i>tert</i> -butyl ({ (5 <i>S</i>)-3-[3-fluoro-4-(3-oxo-3,4-dihydro-2 <i>H</i> -1,4-benzoxazin-6-yl) phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl) carbamate (27)...207	
4.4.8. Synthesis of 6-{4-[(5 <i>S</i>)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl}-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i>)-one hydrochloride (28).....	208
4.4.9. Synthesis of 6-{4-[(5 <i>S</i>)-5-(Acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl}-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i>)-one (29a).....	208
4.4.10. Synthesis of <i>N</i> -({ (5 <i>S</i>)-3-[3-Fluoro-4-(3-oxo-3,4-dihydro-2 <i>H</i> -1,4-benzoxazin-6-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)-2-hydroxyacetamide (29f).....	209
4.4.11. Synthesis of 1-({ (5 <i>S</i>)-3-[3-Fluoro-4-(3-oxo-3,4-dihydro-2 <i>H</i> -1,4-benzoxazin-6-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)guanidine hydrochloride (29j).....	210
4.4.12. Procedure for <i>in vitro</i> antibacterial activity determination.....	210
4.4.13. Procedure of solubility assay.....	211
4.4.14. Procedure of LogD assay.....	212
4.4.15. Procedure of <i>in vitro</i> inhibition assay of CYP ₄₅₀ isoforms.....	212
4.4.16. Procedure for <i>in vitro</i> metabolic stability assay.....	213
4.4.17. Molecular docking protocol.....	214
4.4.18. Spectral data.....	215
4.4.19. ¹ H and ¹³ C NMR spectra.....	227
4.5. References.....	254
Curriculum vitae.....	258

LIST OF FIGURES

Figure No.	Description	Page No.
Figure 1.1.	General representation of heterocycles.....	2
Figure 1.2.	Important heterocyclic compounds found in living systems.....	3
Figure 1.3.	Selected heterocyclic natural products.....	4
Figure 1.4.	Heterocyclic compounds as metal ligands.....	5
Figure 1.5.	Heterocyclic compounds as organocatalyst.....	5
Figure 1.6.	Selected examples of heterocyclic anticancer drugs.....	7
Figure 1.7.	Selected heterocyclic drugs for CNS diseases.....	8
Figure 1.8.	Selected heterocyclic drugs for CVS diseases.....	9
Figure 1.9.	Selected heterocyclic antiviral drugs.....	10
Figure 1.10.	Selected heterocyclic antibacterial drugs.....	10
Figure 2.1.	Biologically active 1,2,3,4-Tetrahydroquinoxalines, 2,3-Dihydro-1,4-benzoxazines, and 1,4-Benzodioxines.....	29
Figure 2.2.	Most potent compounds along with the standard drugs.....	50
Figure 3.1.	Biologically important amido-substituted diaryl and arylheteroarylmethanes.....	108
Figure 3.2.	Time-dependent UV-Vis monitoring of the reaction progress.....	130
Figure 3.3.	Time dependent ¹ H NMR overlay.....	130
Figure 4.1.	Mechanism of action of Oxazolidinones.....	180
Figure 4.2.	Oxazolidinone drugs and clinical candidates.....	182
Figure 4.3.	Oxazolidinone derivative with improved activity against <i>E. coli</i>	185
Figure 4.4.	Oxazolidinone derivative with improved activity against <i>H. influenzae</i>	185
Figure 4.5.	Lipophilic oxazolidinone with improved brain exposure.....	186

Figure 4.6. Oxazolidinone derivatives with fused bicyclic heterocyclic C-ring.....	187
Figure 4.7. <i>In silico</i> docking models: (A) Tedizolid-receptor and (B) 17 -receptor complex...	189
Figure 4.8. Our design strategy.....	189
Figure 4.9. Overlay of 29a (cyan) and 29g (yellow) with Linezolid (green) in receptor binding pocket.....	201
Figure 4.10. <i>In silico</i> docking models: image of ligand-receptor complexes of Linezolid (A), 29a (B), 29g (C).....	202
Figure 4.11. <i>In silico</i> docking models: 2D image of ligand-receptor complexes of Linezolid (A), 22f (B), 22h (C).....	203

LIST OF TABLES

Table No.	Description	Page No.
Table 2.1.	Optimization of reaction conditions for the synthesis of 3a	41
Table 2.2.	Synthesis of substituted 1,2,3,4-tetrahydroquinoxalines.....	44
Table 2.3.	Synthesis of substituted 2,3-dihydro-1,4-benzoxazines.....	45
Table 2.4.	Synthesis of substituted 1,4-benzodioxines.....	46
Table 2.5.	Antibacterial activity results of the synthesized compounds.....	49
Table 3.1.	Reaction optimization for C-benylation of anilide.....	118
Table 3.2.	Substrate scope with anilides and arylcarbamates.....	121
Table 3.3.	Substrate scope with heterocyclic derivatives.....	124
Table 3.4.	C-Benylation of anisole derivatives.....	126
Table 3.5.	<i>In vitro</i> antibacterial activity results of synthesized compounds.....	132
Table 4.1.	Synthesis of targeted oxazolidinone derivatives.....	191
Table 4.2.	<i>In vitro</i> antibacterial activity of compounds with C-ring modifications.....	194
Table 4.3.	<i>In vitro</i> antibacterial activity of compounds with C5-side chain modifications.....	199
Table 4.4.	<i>In vitro</i> Physchem and ADME Results.....	204

LIST OF SCHEMES

Scheme No.	Description	Page No.
Scheme 1.1.	S_NAr reaction by addition-elimination mechanism.....	12
Scheme 1.2.	S_NAr reaction by S_N1 mechanism.....	12
Scheme 1.3.	S_NAr reaction by benzyne mechanism.....	13
Scheme 1.4.	S_NAr reaction by radical pathway.....	13
Scheme 1.5.	Synthesis of Neoamphimedine.....	13
Scheme 1.6.	S_NAr reaction by ANRORC pathway.....	14
Scheme 1.7.	Vicarious nucleophilic substitution.....	14
Scheme 1.8.	Zinc catalyzed allenylation of aldehydes.....	16
Scheme 1.9.	Zinc catalyzed propargylation reactions.....	16
Scheme 1.10.	Zinc catalyzed cyclization reactions.....	17
Scheme 1.11.	Zinc catalyzed asymmetric synthesis.....	18
Scheme 1.12.	Zinc catalyzed cycloaddition reaction.....	18
Scheme 1.13.	Negishi coupling reactions.....	19
Scheme 1.14.	Suzuki coupling in drug synthesis.....	20
Scheme 1.15.	Suzuki coupling in unnatural amino acid synthesis.....	21
Scheme 1.16.	Suzuki coupling in natural product synthesis.....	21
Scheme 2.1.	Iridium catalyzed asymmetric reduction of quinoxaline.....	30
Scheme 2.2.	Bronsted acid catalyzed asymmetric reduction of dihydroquinoxaline.....	31
Scheme 2.3.	Dihydrophenanthroline catalyzed asymmetric reduction of quinoxaline.....	31
Scheme 2.4.	Cationic Ruthenium catalyzed asymmetric reduction of quinoxaline.....	32
Scheme 2.5.	Palladium catalyzed C-N bond formation.....	32

Scheme 2.6. Intramolecular <i>N</i> -alkylation.....	33
Scheme 2.7. Zinc chloride catalyzed hetero-Diels-Alder reaction.....	34
Scheme 2.8. Organo catalyzed hetero-Diels-Alder reaction.....	34
Scheme 2.9. Domino alkylation of 2-amidophenol.....	34
Scheme 2.10. Reduction of benzoxazinones.....	35
Scheme 2.11. Reduction of alkylidenebenzoxazines.....	35
Scheme 2.12. Intramolecular S _N Ar reaction.....	36
Scheme 2.13. Intramolecular O-arylation reaction.....	36
Scheme 2.14. Copper catalyzed aziridine ring opening followed by intramolecular <i>N</i> -arylation.....	37
Scheme 2.15. Nickel catalyzed <i>N</i> -arylation reaction.....	37
Scheme 2.16. Palladium-norbornene catalyzed domino C-C/C-N bond formation.....	38
Scheme 2.17. Quaternary ammonium salt catalyzed domino [5+1] annulation reaction.....	39
Scheme 2.18. Nucleophilic substitution reactions of aromatic nitro group.....	40
Scheme 2.19. Hypothesis for the uncyclised product formation with primary diamine.....	47
Scheme 2.20. Nitro-displacement reaction with primary amine.....	48
Scheme 3.1. Multistep synthesis of diarylmethanes via diazotization approach.....	109
Scheme 3.2. Reduction of benzophenones and benzhydryl alcohols.....	110
Scheme 3.3. Addition reaction of aryl amines with styrene.....	111
Scheme 3.4. Pd and Ni catalyzed cross coupling of aryl bromides with benzyl zinc reagents.....	111
Scheme 3.5. Nickel catalyzed coupling of aryl bromides and benzyltrifluoroborates.....	112
Scheme 3.6. Cross coupling reactions of aryl boronic acids with benzyl methyl carbonates.....	112
Scheme 3.7. Gold catalyzed benzylation of anthranilic acids with benzyl alcohols.....	113
Scheme 3.8. Catellani approach for <i>ortho</i> -C-H benzylation of aryl iodides.....	114

Scheme 3.9. Base mediated <i>N</i> -alkylation of aryl amines.....	115
Scheme 3.10. Base mediated <i>N</i> -alkylation of anilides and cyclic carbamates.....	115
Scheme 3.11. Acid mediated benzylation of anilides.....	115
Scheme 3.12. Cu(OTf) ₂ catalyzed reaction of pivaloylanilide with azido ester.....	117
Scheme 3.13. Reported methods for the synthesis of natural product (76).....	127
Scheme 3.14. Synthesis of 2,4-bis(4-methoxybenzyl)anisole (75).....	128
Scheme 3.15. Plausible mechanism of benzylation reaction.....	129
Scheme 4.1. Synthesis of 6-{4-[(5 <i>S</i>)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl}-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i>)-one hydrochloride (28).....	196
Scheme 4.2. Synthesis of compounds with C5-side chain modifications.....	198

GLOSSARY OF SYMBOLS AND ABBREVIATIONS

Ac	:	Acetyl
acac	:	Acetylacetonate
ADME	:	Absorption, Distribution, Metabolism and Excretion
Al/MCM-41	:	Aluminium grafted mesoporous silica
Aq.	:	Aqueous
Ar	:	Aryl
ATCC	:	American type culture collection
BArF	:	Tetrakis[3,5-bis(trifluoromethyl)phenyl]borate
9-BBN	:	9-Borabicyclononane
BINAP	:	2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl
BINOL	:	1,1'-Bi-2-naphthol
Bn	:	Benzyl
BOC	:	<i>tert</i> -Butyloxycarbonyl
BOD	:	Biochemical oxygen demand
BOX	:	Bis(oxazoline)
B/P ratio	:	Blood to Plasma ratio
bpy	:	2,2'-Bipyridine
Bz	:	Benzoyl
CAMHB	:	Cation-adjusted Mueller-Hinton broth
Cat.	:	Catalyst
CAP	:	Community-acquired pneumonia
CBZ	:	Carboxybenzyl

CETP	:	Cholesteryl ester transfer protein
CFL	:	Compact fluorescent lamp
cfu	:	Colony-forming unit
CLSI	:	Clinical and laboratory standards institute
COD	:	1,5-Cyclooctadiene
Cp*	:	Pentamethylcyclopentadienyl
Cy	:	Cyclohexyl
CYP	:	Cytochrome
dba	:	Dibenzylideneacetone
DCE	:	Dichloroethane
DCM	:	Dichloromethane
DEPT	:	Distortionless enhancement of polarization transfer
Difluorophos	:	5,5'-Bis(diphenylphosphino)-2,2,2',2'-tetrafluoro-4,4'-bi-1,3-benzodioxole
DME	:	Dimethoxyethane
DMF	:	<i>N,N</i> -Dimethylformamide
DMSO	:	Dimethyl sulfoxide
DNA	:	Deoxyribonucleic acid
dppf	:	1,1'-Bis(diphenylphosphino)ferrocene
DPPent	:	1,5-Bis(diphenylphosphino)pentane
dr	:	Diastereomeric ratio
dtbbpy	:	4,4'-Di- <i>tert</i> -butyl-2,2'-dipyridyl
ee	:	Enantiomeric excess
Equiv.	:	Equivalent

ESI	:	Electron spray ionization
EtOAc	:	Ethyl acetate
EtOH	:	Ethanol
Et ₂ O	:	Diethyl ether
EWG	:	Electron withdrawing group
FDA	:	Food and Drug administration
Fmoc	:	Fluorenylmethyloxycarbonyl
GSK	:	GlaxoSmithKline
h	:	Hour
HBA	:	Hydrogen bond acceptor
HBD	:	Hydrogen bond donor
HetAr	:	Heteroaryl
HIV	:	Human immunodeficiency virus
H-mont	:	Proton-exchanged montmorillonite
HMDS	:	Hexamethyldisilazane
HMPA	:	Hexamethylphosphoramide
HMQC	:	Heteronuclear multiple-quantum correlation spectroscopy
HPLC	:	High performance liquid chromatography
HRMS	:	High resolution mass spectroscopy
HTM	:	<i>Haemophilus</i> test medium
H ₈ -BINAPO	:	2,2'-Bis((diphenylphosphino)oxy)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthalene
IDSA	:	Infectious disease society of America

LZD	:	Linezolid
MAO	:	Monoamine oxidase
Me-DuPhos	:	1,2-Bis(2,5-dimethylphospholano)benzene
MeOH	:	Methanol
mg	:	Milligram
MHz	:	Megahertz
MIC	:	Minimum inhibitory concentration
min	:	Minutes
mL	:	Millilitre
mmol	:	Millimole
MRSA	:	Methicillin-resisitant <i>staphylococcus aureus</i>
Ms	:	Methane sulfonyl
M. TB.	:	Mycobacterium tuberculosis
MW	:	Microwave
NADPH	:	Nicotinamide adenine dinucleotide phosphate
NBE	:	Norbornene
NCEs	:	New chemical entities
NHC	:	<i>N</i> -Heterocyclic carbene
NMP	:	<i>N</i> -Methylpyrrolidine
NMR	:	Nuclear magnetic resonance
Nu	:	Nucleophile
PDB	:	Protein data bank
PEG	:	Poly(ethylene glycol)

PG	:	Protecting group
Ph	:	Phenyl
Physchem	:	Physicochemical properties
Pin	:	Pinacol
PipPhos	:	(3,5-Dioxo-4-phosphacyclohepta[2,1-a:3,4-a']dinaphthalen-4-yl) piperidine
Piv	:	Pivaloyl
ppm	:	Parts per million
PTC	:	Phase transfer catalyst
PTFE	:	Polytetrafluoroethylene
<i>p</i> -TSA	:	<i>para</i> -Toluene sulfonic acid
Py	:	Pyridine
Q-Phos	:	1,2,3,4,5-Pentaphenyl-1'-(di- <i>tert</i> -butylphosphino)ferrocene
rt	:	Room temperature
RNA	:	Ribonucleic acid
SEM	:	2-(Trimethylsilyl)ethoxymethyl
S _N Ar	:	Nucleophilic aromatic substitution
S-Phos	:	2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl
TADDOL	:	2,2-Dimethyl- $\alpha,\alpha,\alpha',\alpha'$ -tetraphenyl-dioxolan-4,5-dimethanol
TBAB	:	Tetra- <i>n</i> -butylammonium bromide
TBAF	:	Tetra- <i>n</i> -butylammonium fluoride
TBAI	:	Tetra- <i>n</i> -butylammonium iodide
TBS	:	<i>tert</i> -Butyldimethylsilyl

TEMPO	:	(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl
TEG	:	Triethylene glycol
<i>tert</i>	:	Tertiary
TFA	:	Trifluoroacetic acid
TfO	:	Trifluoromethanesulphonate
THF	:	Tetrahydrofuran
TLC	:	Thin layer chromatography
TMEDA	:	<i>N,N,N',N'</i> -Tetramethylethylenediamine
TMS	:	Trimethylsilyl
TPPMS	:	Sodium triphenylphosphino- <i>m</i> -sulfonate
Ts	:	<i>para</i> -Tolunesulfonyl
UPLC	:	Ultra performance liquid chromatography
uSSSI	:	Uncomplicated skin and skin structure infections
UV	:	Ultraviolet
Vis	:	Visible
VRE	:	Vancomycin-resistant <i>Enterococcus faecalis</i>
WHO	:	World health organization
WT	:	Wild type
X-Phos	:	2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
μL	:	Microlitre

MATERIAL AND METHODS

Physical Measurement

NMR spectra (^1H and ^{13}C) were measured on a Bruker Varian Unity 400 MHz spectrometer (^1H 400 MHz, ^{13}C 100 MHz). HRMS were recorded on MICROTOF-Q II 228888.10262 using electrospray ionization (ESI) as the ionization method. UV-vis spectroscopy was recorded on Lambda Bio 20, Perkin Elmer. HPLC analysis was performed on Alliance HPLC system (Waters, Milliford, USA), using Kromasil C18 HPLC column (5.0 mm, 4.6 mm x 250 mm). Optical rotation was measured on an Autopol V, serial number 80121, manufactured by Rudolph research analytical, Hackettstown, NJ, USA.

Analytical Information

All the isolated compounds were characterized by ^1H NMR, ^{13}C NMR spectroscopy and HRMS using CDCl_3 , D_2O and DMSO as the solvents with tetramethylsilane (TMS) as the internal standard at room temperature. Chemical shifts are given in δ (ppm) relative to TMS, the coupling constants (J) are given in hertz (Hz).

Chemicals and Reagents

All the solvents were bought from commercial vendors (Aldrich, Spectrochem, Alfa-aesar etc) and were used as received. Pre-packed silica gel columns from Biotage and Agela were used for column chromatography. A gradient elution using ethyl acetate: Hexanes or MeOH: DCM were performed on Merck aluminium TLC sheets (silica gel 60F254).